

## AMERICAN MEDICAL ASSOCIATION HOUSE OF DELEGATES

Resolution: 602  
(November 2020)

Introduced by: Women Physicians Section

Subject: Towards Diversity and Inclusion: A Global Nondiscrimination Policy  
Statement and Benchmark for our AMA

Referred to: Reference Committee F

---

1 Whereas, Our AMA has as important goals, the promotion of healthcare diversity, the  
2 improvement of public health, and retention and expansion of membership; and  
3

4 Whereas, Healthcare diversity, and the health of the public is improved when healthcare  
5 providers reflect the diversity of our patients; and  
6

7 Whereas, AMA membership retention, expansion and participation are promoted when  
8 members and prospective members perceive themselves to be welcomed, fully enfranchised,  
9 protected, promoted and supported by their association, free from discrimination, and equally  
10 eligible for leadership; and  
11

12 Whereas, Diversity in healthcare providers is promoted when equal opportunities exist in  
13 employment and leadership within healthcare organizations and in other practice settings; and  
14

15 Whereas, Our AMA is obliged both as a large employer and as a place of public  
16 accommodation to practice nondiscrimination with respect to employment or access on account  
17 of or on the basis of race, color, sex, national origin, age, religion, disability, veteran status,  
18 sexual orientation or other protected characteristics; and  
19

20 Whereas, Our AMA as a nonprofit physician membership association has additional morally  
21 based obligations to lead by example and not to discriminate as an organization on the basis of  
22 age, race, color, creed, gender, gender expression, national origin, locus of medical education  
23 or postgraduate training, cultural ethnicity, sexual orientation, disability, marital status, or military  
24 status, in any of its activities or operations; and  
25

26 Whereas, The Code of Medical Ethics states that physicians “shall respect the rights of patients,  
27 colleagues, and other health professionals, and shall safeguard patient confidences and privacy  
28 within the constraints of the law”; and  
29

30 Whereas, While numerous policies have been enacted over the years by our AMA that address  
31 selected aspects of discrimination by various groups against various groups, these policies are  
32 not uniform and relatively difficult to locate; there are policy gaps and inconsistencies relating to  
33 the lack of an organized approach to addressing the problem of discrimination, making it difficult  
34 to access the applicable policy or policies when a benchmark is needed against which to  
35 measure a proposed action being considered by the organization; and

1 Whereas, While our AMA has a nondiscrimination policy with respect to physician membership  
2 (AMA Bylaws 1-4)<sup>1</sup>, it has at present no overarching nondiscrimination policy as a threshold and  
3 a benchmark tool against which to measure the taking of actions other than membership  
4 decisions, to determine whether entering into new policies, procedures, sponsorships,  
5 endorsements, promotion, legislative or other forms of advocacy, contracts, or proposed  
6 partnerships with other organizations; and

7  
8 Whereas, Without a distinct threshold for consideration of, or benchmark tool against which to  
9 measure proposed organizational actions or partnerships as to potential or actual discriminatory  
10 effect, it is difficult to determine whether pursuit of such actions or partnerships should be  
11 avoided, modified or abandoned so as to avoid discrimination against members with protected  
12 characteristics, contrary to law and organizational moral principles, and to avert any resultant  
13 contravention of AMA ethical principles by those individual physician members involved in  
14 taking the proposed actions or participating in the proposed partnerships; and

15  
16 Whereas, Not all third parties who conduct business with or for our AMA, such as independent  
17 contractors, consultants or vendors, necessarily recognize or independently endorse an  
18 obligation to comply with all applicable laws, rules and regulations; and if they do not comply,  
19 they will, under federal regulations, subject our AMA to potentially significant liability and  
20 adverse publicity; yet third parties are not at present apparently even subject to the published  
21 conflict of interest policy of the AMA; and

22  
23 Whereas, Mandated signatories to the conflict of interest policy (e.g. AMA leaders, key staff and  
24 candidates) must agree to abide by AMA Policy H-140.837, "Policy on Conduct at AMA  
25 Meetings and Events." The current conflict of interest policy refers to anti-harassment (AMA  
26 Policy H-140.837), however, it does not seem to address other forms of discrimination on the  
27 basis of protected characteristics; and

28  
29 Whereas, Our AMA has not adopted a business conduct standards policy making explicit an  
30 obligation that every individual working on AMA business, be they member, employee or  
31 contractor, must adhere to the highest ethical standards, and demonstrate integrity,  
32 professionalism and respect for others and the law, in their dealings with and for the AMA; and

33  
34 Whereas, Our AMA has not widely communicated a comprehensive strategy or program  
35 designed to eliminate bias and enhance diversity and inclusion throughout the association, the  
36 medical profession, and our healthcare system; therefore be it

37  
38 RESOLVED, That our American Medical Association adopt an overarching nondiscrimination  
39 policy on the basis of sex, color, creed, race, religion, disability, ethnic origin, national origin,  
40 sexual orientation, gender identity, age, or for any other reason unrelated to character,  
41 competence, ethics, professional status or professional activities that applies to members,  
42 employees and patients (New HOD Policy); and be it further

43  
44 RESOLVED, That our AMA demonstrate its commitment to complying with laws, rules or  
45 regulations against discrimination on the basis of protected characteristics (Directive to Take  
46 Action); and be it further

---

<sup>1</sup> Membership in the AMA or in any constituent association, national medical specialty society or professional interest medical association represented in the House of Delegates, shall not be denied or abridged because of sex, color, creed, race, religion, disability, ethnic origin, national origin, sexual orientation, gender identity, age, or for any other reason unrelated to character, competence, ethics, professional status or professional activities.

1 RESOLVED, That our AMA reaffirm Policy H-65.988, "Organizations Which Discriminate," and  
2 Policy G-630.040, "Principles on Corporate Relationships," in its overarching non-discrimination  
3 policy (Reaffirm HOD Policy); and be it further  
4

5 RESOLVED, That our AMA reaffirm Policy G-600.067, "References to Terms and Language in  
6 Policies Adopted to Protect Populations from Discrimination and Harassment"; (New HOD  
7 Policy) and be it further  
8

9 RESOLVED, That our AMA study the feasibility and need for a comprehensive business  
10 conduct standards policy to be fully integrated with the conflict of interest policy, and report back  
11 to the AMA House of Delegates within 18 months (Directive to Take Action); and be it further  
12

13 RESOLVED, That our AMA provide an update on its comprehensive diversity and inclusion  
14 strategy to the AMA House of Delegates within 24 months. (Directive to Take Action)

Fiscal Note: Moderate - between \$5,000 - \$10,000

Received: 09/30/20

#### **RELEVANT AMA POLICY**

##### **References to Terms and Language in Policies Adopted to Protect Populations from Discrimination and Harassment G-600.067**

Our AMA will: (1) undertake a study to identify all discrimination and harassment references in AMA policies and the code of ethics, noting when the language is consistent and when it is not; (2) research language and terms used by other national organizations and the federal government in their policies on discrimination and harassment; (3) present the preliminary study results to the Minority Affairs Section, the Women's Physician Section, and the Advisory Committee on LGBTQ Issues to reach consensus on optimal language to protect vulnerable populations including racial and ethnic minorities, sexual and gender minorities, and women, from discrimination and harassment; and (4) produce a report within 18 months with study results and recommendations.

Res. 009, A-19

##### **Discrimination. B-1.4**

Membership in the AMA or in any constituent association, national medical specialty society or professional interest medical association represented in the House of Delegates, shall not be denied or abridged because of sex, color, creed, race, religion, disability, ethnic origin, national origin, sexual orientation, gender identity, age, or for any other reason unrelated to character, competence, ethics, professional status or professional activities.

##### **Support of Human Rights and Freedom H-65.965**

Our AMA: (1) continues to support the dignity of the individual, human rights and the sanctity of human life, (2) reaffirms its long-standing policy that there is no basis for the denial to any human being of equal rights, privileges, and responsibilities commensurate with his or her individual capabilities and ethical character because of an individual's sex, sexual orientation, gender, gender identity, or transgender status, race, religion, disability, ethnic origin, national origin, or age; (3) opposes any discrimination based on an individual's sex, sexual orientation, gender identity, race, religion, disability, ethnic origin, national origin or age and any other such reprehensible policies; (4) recognizes that hate crimes pose a significant threat to the public health and social welfare of the citizens of the United States, urges expedient passage of appropriate hate crimes prevention legislation in accordance with our AMA's policy through letters to members of Congress; and registers support for hate crimes prevention legislation, via letter, to the President of the United States. CCB/CLRPD Rep. 3, A-14; Reaffirmed in lieu of: Res. 001, I-16; Reaffirmation: A-17

### **Discriminatory Policies that Create Inequities in Health Care H-65.963**

Our AMA will: (1) speak against policies that are discriminatory and create even greater health disparities in medicine; and (2) be a voice for our most vulnerable populations, including sexual, gender, racial and ethnic minorities, who will suffer the most under such policies, further widening the gaps that exist in health and wellness in our nation. Res. 001, A-18

### **Principles for Advancing Gender Equity in Medicine H-65.961**

Our AMA:

1. declares it is opposed to any exploitation and discrimination in the workplace based on personal characteristics (i.e., gender);
2. affirms the concept of equal rights for all physicians and that the concept of equality of rights under the law shall not be denied or abridged by the U.S. Government or by any state on account of gender;
3. endorses the principle of equal opportunity of employment and practice in the medical field;
4. affirms its commitment to the full involvement of women in leadership roles throughout the federation, and encourages all components of the federation to vigorously continue their efforts to recruit women members into organized medicine;
5. acknowledges that mentorship and sponsorship are integral components of one's career advancement, and encourages physicians to engage in such activities;
6. declares that compensation should be equitable and based on demonstrated competencies/expertise and not based on personal characteristics;
7. recognizes the importance of part-time work options, job sharing, flexible scheduling, re-entry, and contract negotiations as options for physicians to support work-life balance;
8. affirms that transparency in pay scale and promotion criteria is necessary to promote gender equity, and as such academic medical centers, medical schools, hospitals, group practices and other physician employers should conduct periodic reviews of compensation and promotion rates by gender and evaluate protocols for advancement to determine whether the criteria are discriminatory; and
9. affirms that medical schools, institutions and professional associations should provide training on leadership development, contract and salary negotiations and career advancement strategies that include an analysis of the influence of gender in these skill areas.

Our AMA encourages: (1) state and specialty societies, academic medical centers, medical schools, hospitals, group practices and other physician employers to adopt the AMA Principles for Advancing Gender Equity in Medicine; and (2) academic medical centers, medical schools, hospitals, group practices and other physician employers to: (a) adopt policies that prohibit harassment, discrimination and retaliation; (b) provide anti-harassment training; and (c) prescribe disciplinary and/or corrective action should violation of such policies occur. BOT Rep. 27, A-19

### **9.5.5 Gender Discrimination in Medicine**

Inequality of professional status in medicine among individuals based on gender can compromise patient care, undermine trust, and damage the working environment. Physician leaders in medical schools and medical institutions should advocate for increased leadership in medicine among individuals of underrepresented genders and equitable compensation for all physicians.

Collectively, physicians should actively advocate for and develop family-friendly policies that:

- (a) Promote fairness in the workplace, including providing for:
  - (i) retraining or other programs that facilitate re-entry by physicians who take time away from their careers to have a family;
  - (ii) on-site child care services for dependent children;
  - (iii) job security for physicians who are temporarily not in practice due to pregnancy or family obligations.
- (b) Promote fairness in academic medical settings by:
  - (i) ensuring that tenure decisions make allowance for family obligations by giving faculty members longer to achieve standards for promotion and tenure;
  - (ii) establish more reasonable guidelines regarding the quantity and timing of published material needed for promotion or tenure that emphasize quality over quantity and encourage the pursuit of careers based on individual talent rather than tenure standards that undervalue teaching ability and overvalue research;
  - (iii) fairly distribute teaching, clinical, research, administrative responsibilities, and access to tenure tracks;
  - (iv) structuring the mentoring process through a fair and visible system.
- (c) Take steps to mitigate gender bias in research and publication.

AMA Principles of Medical Ethics: II,VII

*The Opinions in this chapter are offered as ethics guidance for physicians and are not intended to establish standards of clinical practice or rules of law.*

Issued: 2016

### **Organizations Which Discriminate H-65.988**

The AMA (1) encourages holding educational or business meetings or social gatherings in facilities of organizations and clubs which do not refuse membership on the basis of gender, race or religion; and (2) encourages its constituent societies to follow a similar policy. Res. 62, A-87; Reaffirmed: CLRPD Rep. 3, I-97; Reaffirmed: CEJA Rep. 7, A-07; Reaffirmed: CEJA Rep. 04, A-17

### **Principles on Corporate Relationships G-630.040**

The House of Delegates adopts the following revised principles on Corporate Relationships. The Board will review them annually and, if necessary, make recommendations for revisions to be presented to the House of Delegates.

(1) **GUIDELINES FOR AMA CORPORATE RELATIONSHIPS.** Principles to guide AMA's relationships with corporate America were adopted by our AMA House of Delegates at its December 1997 meeting and slightly modified at the June 1998 meeting. Subsequently, they have been edited to reflect the recommendations from the Task Force on Association/Corporate Relations, including among its members experts external to our AMA. Minor edits were also adopted in 2002. The following principles are based on the premise that in certain circumstances, our AMA should participate in corporate arrangements when guidelines are met, which can further our AMA's core strategic focus, retain AMA's independence, avoid conflicts of interest, and guard our professional values.

(2) **OVERVIEW OF PRINCIPLES.** The AMA's principles to guide corporate relationships have been organized into the following categories: General Principles that apply to most situations; Special Guidelines that deal with specific issues and concerns; Organizational Review that outlines the roles and responsibilities of the Board of Trustees, AMA Management and other staff units. These guidelines should be reviewed over time to assure their continued relevance to the policies and operations of our AMA and to our business environment. The principles should serve as a starting point for anyone reviewing or developing AMA's relationships with outside groups.

(3) **GENERAL PRINCIPLES.** Our AMA's vision and values statement and strategic focus should provide guidance for externally funded relationships. Relations that are not motivated by the association's mission threaten our AMA's ability to provide representation and leadership for the profession.

(a) Our AMA's vision and values and strategic focus ultimately must determine whether a proposed relationship is appropriate for our AMA. Our AMA should not have relationships with organizations or industries whose principles, policies or actions obviously conflict with our AMA's vision and values. For example, relationships with producers of products that harm the public health (e.g., tobacco) are not appropriate for our AMA. Our AMA will proactively choose its priorities for external relationships and collaborate in those that fulfill these priorities.

(b) The relationship must preserve or promote trust in our AMA and the medical profession. To be effective, medical professionalism requires the public's trust. Corporate relationships that could undermine the public's trust in our AMA or the profession are not acceptable. For example, no relationship should raise questions about the scientific content of our AMA's health information publications, AMA's advocacy on public health issues, or the truthfulness of its public statements.

(c) The relationship must maintain our AMA's objectivity with respect to health issues. Our AMA accepts funds or royalties from external organizations only if acceptance does not pose a conflict of interest and in no way impacts the objectivity of the association, its members, activities, programs, or employees. For example, exclusive relationships with manufacturers of health-related products marketed to the public could impair our AMA's objectivity in promoting the health of America. Our AMA's objectivity with respect to health issues should not be biased by external relationships.

(d) The activity must provide benefit to the public's health, patients' care, or physicians' practice. Public education campaigns and programs for AMA or Federation members are potentially of significant benefit. Corporate-supported programs that provide financial benefits to our AMA but no significant benefit to the public or direct professional benefits to AMA or Federation members are not acceptable. In the case of member benefits, external relations must not detract from AMA's professionalism.

(4) **SPECIAL GUIDELINES.** The following guidelines address a number of special situations where our AMA cannot utilize external funding. There are specific guidelines already in place regarding advertising in publications.

(a) Our AMA will provide health and medical information, but should not involve itself in the production, sale, or marketing to consumers of products that claim a health benefit. Marketing health-related products (e.g., pharmaceuticals, home health care products) undermines our AMA's objectivity and diminishes its role in representing healthcare values and educating the public about their health and healthcare.

(b) Activities should be funded from multiple sources whenever possible. Activities funded from a single external source are at greater risk for inappropriate influence from the supporter or the perception of it, which may be equally damaging. For example, funding for a patient education brochure should be done with multiple sponsors if possible. For the purposes of this guideline, funding from several companies, but each from a

different and non-competing industry category (e.g., one pharmaceutical manufacturer and one health insurance provider), does not constitute multiple-source funding. Our AMA recognizes that for some activities the benefits may be so great, the harms so minimal, and the prospects for developing multiple sources of funding so unlikely that single-source funding is a reasonable option. Even so, funding exclusivity must be limited to program only (e.g., asthma conference) and shall not extend to a therapeutic category (e.g., asthma). The Board should review single-sponsored activities prior to implementation to ensure that: (i) reasonable attempts have been made to locate additional sources of funds (for example, issuing an open request for proposals to companies in the category); and (ii) the expected benefits of the project merit the additional risk to our AMA of accepting single-source funding. In all cases of single-source funding, our AMA will guard against conflict of interest.

(c) The relationship must preserve AMA's control over any projects and products bearing our AMA name or logo. Our AMA retains editorial control over any information produced as part of a corporate/externally funded arrangement. When an AMA program receives external financial support, our AMA must remain in control of its name, logo, and AMA content, and must approve all marketing materials to ensure that the message is congruent with our AMA's vision and values. A statement regarding AMA editorial control as well as the name(s) of the program's supporter(s) must appear in all public materials describing the program and in all educational materials produced by the program. (This principle is intended to apply only to those situations where an outside entity requests our AMA to put its name on products produced by the outside entity, and not to those situations where our AMA only licenses its own products for use in conjunction with another entity's products.)

(d) Relationships must not permit or encourage influence by the corporate partner on our AMA. An AMA corporate relationship must not permit influence by the corporate partner on AMA policies, priorities, and actions. For example, agreements stipulating access by corporate partners to the House of Delegates or access to AMA leadership would be of concern. Additionally, relationships that appear to be acceptable when viewed alone may become unacceptable when viewed in light of other existing or proposed activities.

(e) Participation in a sponsorship program does not imply AMA's endorsement of an entity or its policies. Participation in sponsorship of an AMA program does not imply AMA approval of that corporation's general policies, nor does it imply that our AMA will exert any influence to advance the corporation's interests outside the substance of the arrangement itself. Our AMA's name and logo should not be used in a manner that would express or imply an AMA endorsement of the corporation, its policies and/or its products.

(f) To remove any appearance of undue influence on the affairs of our AMA, our AMA should not depend on funding from corporate relationships for core governance activities.

Funding core governance activities from corporate sponsors, i.e., the financial support for conduct of the House of Delegates, the Board of Trustees and Council meetings could make our AMA become dependent on external funding for its existence or could allow a supporter, or group of supporters, to have undue influence on the affairs of our AMA.

(g) Funds from corporate relationships must not be used to support political advocacy activities. A full and effective separation should exist, as it currently does, between political activities and corporate funding. Our AMA should not advocate for a particular issue because it has received funding from an interested corporation. Public concern would be heightened if it appeared that our AMA's advocacy agenda was influenced by corporate funding.

(5) ORGANIZATIONAL REVIEW. Every proposal for an AMA corporate relationship must be thoroughly screened prior to staff implementation. AMA activities that meet certain criteria requiring further review are forwarded to a committee of the Board of Trustees for a heightened level of scrutiny.

(a) As part of its annual report on the AMA's performance, activities, and status, the Board of Trustees will present a summary of the AMA's corporate arrangements to the House of Delegates at each Annual Meeting.

(b) Every new AMA Corporate relationship must be approved by the Board of Trustees, or through a procedure adopted by the Board. Specific procedures and policies regarding Board review are as follows: (i) The Board routinely should be informed of all AMA corporate relationships; (ii) Upon request of two dissenting members of the CRT, any dissenting votes within the CRT, and instances when the CRT and the Board committee differ in the disposition of a proposal, are brought to the attention of the full Board; (iii) All externally supported corporate activities directed to the public should receive Board review and approval; (iv) All activities that have support from only one corporation except patient materials linked to CME, within an industry should either be in compliance with ACCME guidelines or receive Board review; and (f) All relationships where our AMA takes on a risk of substantial financial penalties for cancellation should receive Board review prior to enactment.

(c) The Executive Vice President is responsible for the review and implementation of each specific arrangement according to the previously described principles. The Executive Vice President is responsible for obtaining the Board of Trustees authorization for externally funded arrangements that have an economic and/or policy impact on our AMA.

(d) The Corporate Review Team reviews corporate arrangements to ensure consistency with the principles and guidelines. (i) The Corporate Review Team is the internal, cross-organizational group that is charged with the

review of all activities that associate the AMA's name and logo with that of another entity and/or with external funding. (ii) The Review process is structured to specifically address issues pertaining to AMA's policy, ethics, business practices, corporate identity, reputation and due diligence. Written procedures formalize the committee's process for review of corporate arrangements. (iii) All activities placed on the Corporate Review Team agenda have had the senior manager's review and consent, and following CRT approval will continue to require the routine approvals of the Office of Finance and Office of the General Counsel. (iv) The Corporate Review Team reports its findings and recommendations directly to a committee of the Board.

(e) Our AMA's Office of Risk Management in consultation with the Office of the General Counsel will review and approve all marketing materials that are prepared by others for use in the U.S. and that bear our AMA's name and/or corporate identity. All marketing materials will be reviewed for appropriate use of AMA's logos and trademarks, perception of implied endorsement of the external entity's policies or products, unsubstantiated claims, misleading, exaggerated or false claims, and reference to appropriate documentation when claims are made. In the instance of international publishing of JAMA and the Archives, our AMA will require review and approval of representative marketing materials by the editor of each international edition in compliance with these principles and guidelines.

**(6) ORGANIZATIONAL CULTURE AND ITS INFLUENCE ON EXTERNALLY FUNDED PROGRAMS.**

(a) Organizational culture has a profound impact on whether and how AMA corporate relationships are pursued. AMA activities reflect on all physicians. Moreover, all physicians are represented to some extent by AMA actions. Thus, our AMA must act as the professional representative for all physicians, and not merely as an advocacy group or club for AMA members.

(b) As a professional organization, our AMA operates with a higher level of purpose representing the ideals of medicine. Nevertheless, non-profit associations today do require the generation of non-dues revenues. Our AMA should set goals that do not create an undue expectation to raise increasing amounts of money. Such financial pressures can provide an incentive to evade, minimize, or overlook guidelines for fundraising through external sources.

(c) Every staff member in the association must be accountable to explicit ethical standards that are derived from the vision, values, and focus areas of the Association. In turn, leaders of our AMA must recognize the critical role the organization plays as the sole nationally representative professional association for medicine in America. AMA leaders must make programmatic choices that reflect a commitment to professional values and the core organizational purpose. (BOT Rep. 20, A-99; Consolidated: CLRPD Rep. 3, I-01; Modified: CLRPD Rep. 1, A-03; Modified: CCB/CLRPD Rep. 3, A-12)

**Retirement and Hiring Practices H-25.996**

It is urged that physicians, individually and through their constituent, component, and specialty medical societies, continue to stress the need to reappraise policies calling for compulsory retirement and age discrimination in hiring from the standpoint of health among older people, and that they participate actively and lend medical weight in the efforts of other groups to create a new climate of opportunity for the older worker. Committee on Aging Report, I-62; Reaffirmed: CLRPD Rep. C, A-88; Reaffirmed: Sunset Report, I-98; Reaffirmed: CSAPH Rep. 2, A-08; Modified: CCB Rep. 01, A-18